Analysis of PI3K/AKT/MTOR signalling pathway in high risk neuroblastic tumours

Polish Journal of Pathology

Volumn 61, Issue 4, 2010, Pages 192-198

  Izycka Świeszewska, Ewa ^a   Drozyńska, Elzbieta ^a   Rzepko, Robert ^b   Kobierska Gulida, Grazyna ^a   Grajkowska, Wieslawa ^c   Perek, Danuta ^c   Balcerska, Anna ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Individual Private Medical Practice   (Poland)

^c CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

High risk; Intracellular signaling; Neuroblastoma; PI3K AKT mTOR pathway

Indexed keywords

MTOR PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ABDOMINAL TUMOR; ADOLESCENT; ADRENAL TUMOR; ARTICLE; CANCER STAGING; CELL NUCLEUS; CHILD; HUMAN; INFANT; METABOLISM; NEUROBLASTOMA; PATHOLOGY; PRESCHOOL CHILD; SIGNAL TRANSDUCTION;

ABDOMINAL NEOPLASMS; ADOLESCENT; ADRENAL GLAND NEOPLASMS; CELL NUCLEUS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; NEOPLASM STAGING; NEUROBLASTOMA; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 79953319630     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Brodeur G. Neuroblastoma: biological insight into a clinical enigma. Nature Rev 2003; 3: 203-216.
2. Maris J, Hogarty M, Bagatell R, Cohn S. Neuroblastoma. Lancet 2007; 369: 2106-2120.
3. Modak S, Cheung N. Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat Rev 2010; 36: 307-317.
4. Shimada H, Ambros I, Dehner L. The International Neuroblastoma Pathology Classification (the Shimada System). Cancer 1999; 86: 364-372.
5. Monclair T, Brodeur G, Ambros P, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG task force report. J Clin Oncol 2008; 27: 298-303.
6. Cohn S, Pearson A, London W, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27: 289-297.
7. Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006; 18: 77-82.
8. Markman B, Atzori F, Perez-Garcia J, et al. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 2010; 21: 683-691.
9. Kok K, Geering B, Vanhaesebroeck B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci 2009; 34: 115-127.
10. Cheng C, Fan Q, Weiss W. PI3K signaling in glioma-animal models and therapeutic challenges. Brain Pathology 2009; 19: 112-120.
11. Mamame Y, Petroulakis E, LeBacquer O, Sonenberg N. MTOR, translation initiation and cancer. Oncogene 2006; 25: 6416-6422.
12. Vignot S, Faivre S, Aguirre D, Raymond E. MTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16: 525-37.
13. Armegnol G, Rojo F, Castellvi J, et al. 4E-Binding Protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 2007; 67: 7551-7555.
14. Opel D, Poremba C, Simon T, et al. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 2007; 67: 735-745.
15. Boller D, Schramm A, Doepfner K, et al. Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clin Cancer Res 2008; 14: 1172-1181.
16. Johnsen J, Segerstrom L, Orrego A, et al. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 2008; 27:2910-2922.
17. Zeng M, Zhou J. Roles of autophagy and mTOR signaling in neuronal differentiation of mouse neuroblastoma cells. Cellular Signalling 2008; 20:659-665.
18. Ishola T, Kang J, Ciao J, ae al. Phosphatidylinositol 3-kinase regulation of gastrin-releasing peptide-induced cell cycle progression in neuroblastoma cells. Biochim Biophys Acta 2007; 1770: 927-932.
19. Pituch-Noworolska A, Zaremba M, Wieczorek A. Expression of proteins associated with therapy resistance in rhabdomyosarcoma and neuroblastoma tumour cells. Pol J Pathol 2009; 60: 168-73.
20. Gorlick R, Kolb E, Houghton P, et al. Initial resting (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2009; 53: 594-598.
21. Houghton P, Morton C, Gorlick R, et al. Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther 2010; 9: 101-112.
22. Salmena L, Carracedo A, Pandolfi P. Tenets of PTEN tumor suppression. Cell 2008; 133 DOI 10.1016/j. cell.2008.04.013
23. Dam V, Morgan B, Mazanek P, Hogarty M. Mutations in PI3KCA are infrequent in neuroblastoma. BMC Cancer 2006; 6: 177.
24. Munoz J, Lazcoz P, Inda M, et al. Homozygous deletion and expression of PTEN and DMBT1 in human primary neuroblastoma and cell lines. Int J Cancer 2004; 109: 673-679.
25. Richards K, Zweidler-mcKay P, Van Roy N, et al. Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo. Cancer 2010; 116: 3233-3243.
26. Schramm A, Schulte J, Astrahantseff K. Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Letters 2005; 228: 143-53.
27. Ho R, Minturn J, Hishiki T, et al. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 2005; 65: 9868-9875.
28. Kim B, van Golen C, Feldamn E. Insulin-like growth factor-I signaling in human neuroblastoma cells. Oncogene 2004; 23: 130-141.
29. Wlodarski P, Baszczyk A, Grajkowska W, et al. Implication of active Erk in the classic type of human medulloblastoma. Folia Neuropathol 2008; 46: 117-122.
30. Choe G, Horvath S, Cloughesy T, et al. Analysis of the Phosphatidylinositol 3'-Kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003; 63: 2742-2746
31. Xu G, Zhang W, Bertram P, et al. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 2004; 24: 893-900.
32. Hartmann W, Kuchler J, Koch A, et al. Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival. Clin Cancer Res 2009; 12: 4538-4545.
33. Presneau N, Shalaby A, Idowu B, et al. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway. Br J Cancer 2009; 100: 1406-1414.
34. Brown R, Tan D, Taylor J, et al. Morphoproteomic confirmation of constutively activated mTOR, ERK, and NF-kappaB pathways in high risk neuroblastoma, with cell cycle and protein analyte correlates. Ann Clin Lab Sci 2007; 37: 141-147.
35. Qiao J, Kang J, Cree J, et al. Gastrin-Realising Peptide-Induced down-regulation of tumor suppressor protein PTEN in neuroblastomas. Ann Surg 2005; 241: 684-692.
36. Molenaar J, Ebus M, Koster J, et al. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res 2008; 68: 2599-2609.